Moderna, Inc., a biopharma company developing messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a developer of cell-free DNA synthesis and amplification technologies based in Japan, have entered into a definitive agreement under which Moderna will acquire OriCiro for $85 million.   “With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,” said Stéphane Bancel,...